Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain
Biotech
Lundbeck slashes value of $250M Abide buyout after pain setback
Lundbeck is slashing the book value of its $250 million Abide buyout in response to phase 1 data that triggered an early end to a pain program.
Nick Paul Taylor
Oct 24, 2024 7:20am
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Aug 19, 2024 5:27am
The neural circuits behind the placebo effect
Jul 24, 2024 9:02am
AI may influence whether you can get pain medication
Aug 31, 2023 9:25am
Gene therapy reduces chronic pain and chemo-induced neuropathy
Jul 31, 2023 9:30am
Heron lays off 25% of staff in second round of cuts in 13 months
Jul 24, 2023 12:44pm